Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4726 - 4750 of 5845 in total
Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
Investigational
Matched Description: … Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's …
Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).
Investigational
Matched Description: … Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia). …
Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).
Investigational
Matched Description: … investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment
mRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.
Investigational
Matched Description: … ., it is being investigated for the treatment of methylmalonic academia.[A258843] …
ASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.
Investigational
Matched Description: … Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093] …
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Investigational
Matched Description: … [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis …
Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. It has subsequently been developed...
Investigational
Matched Description: … It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects ... It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. …
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Description: … Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. …
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … In Japan, the company Mochida started its commercialization for the treatment of depression started in …
Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
Investigational
Matched Description: … Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer …
9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among others.
Investigational
Matched Description: … 9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu …
ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.
Investigational
Matched Description: … ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease. …
Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment).
Investigational
Matched Description: … Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo. It is under investigation for the treatment of ovarian cancer.
Investigational
Matched Description: … It is under investigation for the treatment of ovarian cancer. …
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Investigational
Matched Description: … BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. …
Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.
Withdrawn
Matched Description: … Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment
Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.
Investigational
Matched Description: … Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter …
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Experimental
Matched Description: … It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. …
ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.
Investigational
Matched Description: … In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341] …
AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL). It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.
Investigational
Matched Description: … It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22. …
ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.
Investigational
Matched Description: … ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of …
A metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome.
Investigational
Matched Description: … Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome. …
Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Investigational
Matched Description: … It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis. …
AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Investigational
Matched Description: … AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. …
Displaying drugs 4726 - 4750 of 5845 in total